The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases

Autoimmunity Reviews

Volumn 9, Issue 12, 2010, Pages 835-839

  Atzeni, Fabiola ^a   Turiel, Maurizio ^b   Caporali, Roberto ^c   Cavagna, Lorenzo ^c   Tomasoni, Livio ^b   Sitia, Simona ^b   Sarzi Puttini, Piercarlo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Anti TNF agents; Autoimmune disease; Biological agents; Disease modifying antirheumatic drugs; Mortality; Tocilizumab

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; CELECOXIB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DICLOFENAC; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FOLIC ACID; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; INFLIXIMAB; LEFLUNOMIDE; LIPID; METHOTREXATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; ROFECOXIB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; UNINDEXED DRUG;

ACUTE HEART INFARCTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CORONARY ARTERY ATHEROSCLEROSIS; CORTICOSTEROID THERAPY; DOSE RESPONSE; DRUG EFFECT; DRUG EXPOSURE; DRUG MEGADOSE; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HEART FAILURE; HUMAN; HYPERHOMOCYSTEINEMIA; INFLAMMATION; LOW DRUG DOSE; MORBIDITY; MORTALITY; PAIN; RECOMMENDED DRUG DOSE; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; STATISTICAL SIGNIFICANCE; STROKE; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; UNSPECIFIED SIDE EFFECT;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION;

EID: 77956925678     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2010.07.018     Document Type: Review

References (40)

1. Nurmohamed M.T. Cardiovascular risk in rheumatoid arthritis. Autoimmunity Reviews 2009, 8:663-667.
2. Bartoloni E., Alunno A., Bistoni O., Gerli R. How early is the atherosclerotic risk in rheumatoid arthritis?. Autoimmun Rev 2010 Jun 11, [Epub ahead of print].
3. Bresalier R.S., Sandler R.S., Quan H., Bolognese J.A., Oxenius B., Horgan K., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005, 352:1092-1102.
4. Alacqua M., Trifirò G., Cavagna L., Caporali R., Montecucco C., Moretti S., et al. Prescribing pattern of drugs in the treatment of osteoarthritis in Italian general practice: the effect of rofecoxib withdrawal. Arthritis Rheum 2008, 59:568-574.
5. Caldwell B., Aldington S., Weatherall M., Shirtcliffe P., Beasley R. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med 2006, 99:132-140.
6. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials 2006, 1:e33. ADAPT Research Group.
7. van der Linden M.W., van der Bij S., Welsing P., Kuipers E.J., Herings R.M. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis 2009, 68:668-673.
8. Gislason G.H., Rasmussen J.N., Abildstrom S.Z., Schramm T.K., Hansen M.L., Fosbøl E.L., et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med 2009, 169:141-149.
9. Solomon D.H., Glynn R.J., Rothman K.J., Schneeweiss S., Setoguchi S., Mogun H., et al. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum 2008, 59:1097-1104.
10. Hahn B.H., Grossman J., Ansell B.J., Skaggs B.J., McMahon M. Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2008, 10:213.
11. Caporali R., Cimmino M.A., Sarzi-Puttini P., Scarpa R., Parazzini F., Zaninelli A., et al. Comorbid conditions in the AMICA study patients: effects on the quality of life and drug prescriptions by general practitioners and specialists. Semin Arthritis Rheum 2005, 35(S1):31-37.
12. Caporali R., Montecucco C. Cardiovascular effects of coxibs. Lupus 2005, 14:785-788.
13. Ruyssen-Witrand A., Fautrel B., Sarauxc A., Le Loëtd X., Phame T. Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review. Joint Bone Spine 2010, [pubemed in print].
14. Wolfe F., Michaud K. The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis. Arthritis Rheum 2008, 58:2612-2621.
15. Davis J.M., Maradit Kremers H., Crowson C.S., Nicola P.J., Ballman K.V., Therneau T.M., et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2007, 56:820-830.
16. del Rincon I., Pogosian S., Escalante A. Daily and cumulative threshold glucocorticoid dose associated with cardiovascular and all-cause mortality in rheumatoid arthritis. Arthritis Rheum 2007, 56. [Abstract [289]].
17. Gonzalez-Gay M.A., Gonzalez-Juanatey C., Lopez-Diaz M.J., Piñeiro A., Garcia-Porrua C., Miranda-Filloy J.A., et al. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007, 57:125-132.
18. Palinski W., Napoli C. Unraveling pleiotropic effects of statins on plaque rupture. Arterioscler Thromb Vasc Biol. 2002, 22:1745-1750.
19. McCarey D.W., McInnes I.B., Madhok R., Hampson R., Scherbakov O., Ford I., et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet. 2004, 363:2015-2021.
20. Westlake S.L., Colebatch A.N., Baird J., Kiely P., Quinn M., Choy E., et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford). 2010, 49:295-307.
21. Landewe R.B., van den Borne B.E., Breedveld F.C., Dijkmans B.A. Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity. Lancet 2000, 355:1616-1617.
22. Choi H.K., Hernan M.A., Seeger J.D., Robins J.M., Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002, 359:1173-1177.
23. Bernatsky S., Hudson M., Suissa S. Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford) 2005, 44:677-680.
24. van Halm V.P., Nurmohamed M.T., Twisk J.W., Dijkmans B.A., Voskuyl A.E. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 2006, 8:R151.
25. Rozman B., Praprotnik S., Logar D., Tomsic M., Hojnik M., Kos- Golja M., et al. Leflunomide and hypertension. Ann Rheum Dis 2002, 61:567-569.
26. Suissa S., Bernatsky S., Hudson M. Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis Rheum 2006, 55:531-536.
27. Solomon D.H., Avorn J., Katz J.N., Weinblatt M.E., Setoguchi S., Levin R., et al. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54:3790-3798.
28. Park Y.B., Choi H.K., Kim M.Y., Lee W.K., Song J., Kim D.K., et al. Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. Am J Med 2002, 113:188-193.
29. Georgiadis A.N., Papavasiliou E.C., Lourida E.S., Alamanos Y., Kostara C., Tselepis A.D., et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment - a prospective, controlled study. Arthritis Res Ther 2006, 8:R82.
30. Boers M., Nurmohamed M.T., Doelman C.J., Lard L.R., Verhoeven A.C., Voskuyl A.E., et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 2003, 62:842-845.
31. Ruiz-Irastorza G., Ramos-Casals M., Brito-Zeron P., Khamashta M.A. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010, 69:20-28.
32. Dixon W.G., Symmons D.P. What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology. Ann Rheum Dis. 2007, 66:1132-1136.
33. Gonzalez-Gay M.A., De Matias J.M., Gonzalez-Juanatey C., Garcia-Porrua C., Sanchez-Andrade A., Martin J., et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2006, 24:83-86.
34. Hürlimann D., Forster A., Noll G., Enseleit F., Chenevard R., Distler O., et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002, 22(106):2184-2187.
35. Gonzalez-Juanatey C., Testa A., Garcia-Castelo A., Garcia-Porrua C., Llorca J., Gonzalez-Gay M.A. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum. 2004, 51:447-450.
36. Sidiropoulos P.I., Siakka P., Pagonidis K., Raptopoulou A., Kritikos H., Tsetis D., et al. Sustained improvement of vascular endothelial function during anti-TNFalpha treatment in rheumatoid arthritis patients. Scand J Rheumatol. 2009, 38:6-10.
37. Turiel M., Tomasoni L., Sitia S., Cicala S., Gianturco L., Ricci C., et al. Effects of long-term disease-modifying antirheumatic drugs on endothelial function in patients with early rheumatoid arthritis. Cardiovasc Ther 2010 Mar 10, [Epub ahead of print].
38. Sarzi-Puttini P., Atzeni F., Shoenfeld Y., Ferraccioli G. TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma. Autoimmun Rev. 2005, 4:153-161.
39. Gonzalez-Juanatey C., Llorca J., Vazquez-Rodriguez T.R., Diaz-Varela N., Garcia-Quiroga H., Gonzalez-Gay M.A. Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy. Arthritis Rheum. 2008, 59:1821-1824.
40. Senolt L., Vencovskỳ J., Pavelka K., Ospelt C., Gay S. Prospective new biological therapies for rheumatoid arthritis. Autoimmun Rev. 2009, 9:102-107.